Rossari Q1: revenue surges 28% YoY, but consolidated PAT up just 4% as margins compress

Rossari Biotech's Q1 FY27 is a topline-beat, bottom-line-soft print. Consolidated revenue rose 28.2% YoY to ₹697.2 Cr — comfortably ahead of management's minimum 15% FY27 growth guidance — but consolidated PAT grew only 4.5% YoY to ₹35.1 Cr and fell 23.7% sequentially. Net margin slipped to 5.0% (from 6.2% a year ago and 6.5% in Q4), and operating margin of ~11.6% sat just below the guided 12-13% EBITDA band. The QoQ profit drop is partly a base effect: Q4 carried ₹19.1 Cr of other income against only ₹3.2 Cr this quarter, but the underlying issue is gross-margin erosion — cost of materials (net of stock changes) climbed to ~70% of sales from ~68% a year earlier, meaning volume-led revenue is not fully converting to profit.

The standalone (parent) numbers tell a materially better story than the group: standalone revenue rose 31.9% YoY to ₹482.3 Cr and standalone PAT jumped 30.6% to ₹34.3 Cr at a 7.1% net margin. Nearly all consolidated profit therefore came from the parent — the subsidiaries (five reported thin or loss-making, per the auditor) diluted group profitability, and this >25-point divergence between standalone and consolidated PAT growth is the quarter's key nuance for readers comparing the two figures. Finance costs also nearly doubled YoY to ₹11.0 Cr, a point to watch against management's stated aim of becoming debt-free within 18 months.

The stock went into the print at ₹534.5, up 4.9% over the past month of trading.

For context: revenue is at a 6-quarter high.

Against the street, this reads as a miss on the metric that mattered: previews flagged a ~14% EBITDA-margin threshold and 15-20% FY27 PAT growth as the bull case, and Q1 delivered neither on profitability despite the revenue beat. Alongside the results the Board approved a 4,000-option ESOP grant and the intra-group transfer of Rossari International (RILC) to Rossari Singapore (~₹24 Cr, no material P&L impact) as part of overseas-subsidiary consolidation. No management press release was extracted; the concall is scheduled for July 20, where the margin bridge and cost pass-through in pharma/agro/oil & gas will be the focus.